|
1
|
Moffitt RA, Marayati R, Flate EL, Volmar
KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung
AH, et al: Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat
Genet. 47:1168–1178. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou L, Yao LT, Liang ZY, Zhou WX, You L,
Shao QQ, Huang S, Guo JC and Zhao YP: Nuclear translocation of
fibroblast growth factor receptor 3 and its significance in
pancreatic cancer. Int J Clin Exp Pathol. 8:14640–14648.
2015.PubMed/NCBI
|
|
3
|
Onyeaghala G, Nelson HH, Thyagarajan B,
Linabery AM, Panoskaltsis-Mortari A, Gross M, Anderson KE and
Prizment AE: Soluble MICA is elevated in pancreatic cancer: Results
from a population based case-control study. Mol Carcinog.
56:2158–2164. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu Y, Liu L, Ma R, Gong H, Xu P and Wang
C: MicroRNA-127 is aberrantly downregulated and acted as a
functional tumor suppressor in human pancreatic cancer. Tumour
Biol. 37:14249–14257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang XP, Liu SL, Xu JF, Cao SG, Li Y and
Zhou YB: Pancreatic stellate cells increase pancreatic cancer cells
invasion through the hepatocyte growth factor/c-Met/survivin
regulated by P53/P21. Exp Cell Res. 357:79–87. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jixiang C, Shengchun D, Jianguo Q, Zhengfa
M, Xin F, Xuqing W, Jianxin Z and Lei C: YEATS4 promotes the
tumorigenesis of pancreatic cancer by activating beta-catenin/TCF
signaling. Oncotarget. 8:25200–25210. 2017.PubMed/NCBI
|
|
7
|
Silverman BR and Shi J: Alterations of
epigenetic regulators in pancreatic cancer and their clinical
implications. Int J Mol Sci. 17:pii: E2138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mao Y, Shen J, Lu Y, Lin K, Wang H, Li Y,
Chang P, Walker MG and Li D: RNA sequencing analyses reveal novel
differentially expressed genes and pathways in pancreatic cancer.
Oncotarget. 8:42537–42547. 2017.PubMed/NCBI
|
|
9
|
Wang J, Guo XJ, Ding YM and Jiang JX:
miR-1181 inhibits invasion and proliferation via STAT3 in
pancreatic cancer. World J Gastroenterol. 23:1594–1601. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vandenberg JI, Perry MD, Perrin MJ, Mann
SA, Ke Y and Hill AP: hERG K(+) channels: Structure, function, and
clinical significance. Physiol Rev. 92:1393–1478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Villoutreix BO and Taboureau O:
Computational investigations of hERG channel blockers: New insights
and current predictive models. Adv Drug Deliv Rev. 86:72–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cubeddu LX: Drug-induced inhibition and
trafficking disruption of ion channels: Pathogenesis of QT
abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev.
12:141–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perez-Neut M, Haar L, Rao V, Santha S,
Lansu K, Rana B, Jones WK and Gentile S: Activation of hERG3
channel stimulates autophagy and promotes cellular senescence in
melanoma. Oncotarget. 7:21991–22004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Becchetti A, Crescioli S, Zanieri F,
Petroni G, Mercatelli R, Coppola S, Gasparoli L, D'Amico M,
Pillozzi S, Crociani O, et al: The conformational state of hERG1
channels determines integrin association, downstream signaling, and
cancer progression. Sci Signal. 10:pii: eaaf3236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arcangeli A and Becchetti A: hERG
channels: From antitargets to novel targets for cancer therapy.
Clin Cancer Res. 23:3–5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rachagani S, Macha MA, Heimann N,
Seshacharyulu P, Haridas D, Chugh S and Batra SK: Clinical
implications of miRNAs in the pathogenesis, diagnosis and therapy
of pancreatic cancer. Adv Drug Deliv Rev. 81:16–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun B, Liu X, Gao Y, Li L and Dong Z:
Downregulation of miR-124 predicts poor prognosis in pancreatic
ductal adenocarcinoma patients. Br J Biomed Sci. 73:152–157. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai H, An Y, Chen X, Sun D, Chen T, Peng
Y, Zhu F, Jiang Y and He X: Epigenetic inhibition of miR-663b by
long non-coding RNA HOTAIR promotes pancreatic cancer cell
proliferation via up-regulation of insulin-like growth factor 2.
Oncotarget. 7:86857–86870. 2016.PubMed/NCBI
|
|
20
|
Schultz NA, Dehlendorff C, Jensen BV,
Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE,
Yilmaz M, Holländer NH, et al: MicroRNA biomarkers in whole blood
for detection of pancreatic cancer. JAMA. 311:392–404. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kato K, Iwama H, Yamashita T, Kobayashi K,
Fujihara S, Fujimori T, Kamada H, Kobara H and Masaki T: The
anti-diabetic drug metformin inhibits pancreatic cancer cell
proliferation in vitro and in vivo: Study of the
microRNAs associated with the antitumor effect of metformin. Oncol
Rep. 35:1582–1592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Debska G, Kicinska A, Skalska J and
Szewczyk A: Intracellular potassium and chloride channels: An
update. Acta Biochim Pol. 48:137–144. 2001.PubMed/NCBI
|
|
23
|
Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang
W, Wang B, Yang L, Xu H, Zhang G and Xu Z: HERG1 functions as an
oncogene in pancreatic cancer and is downregulated by miR-96.
Oncotarget. 5:5832–5844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pengcheng S, Ziqi W, Luyao Y, Xiangwei Z,
Liang L, Yuwei L, Lechen L and Wanhai X: MicroRNA-497 suppress
renal cell carcinoma by targeting VEGFR-2 in ACHN cells. Biosci
Rep. 37:pii: BSR20170270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang K, Zhang C, Liu L and Zhou J: A key
role of microRNA-29b in suppression of osteosarcoma cell
proliferation and migration via modulation of VEGF. Int J Clin Exp
Pathol. 7:5701–5708. 2014.PubMed/NCBI
|
